The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
Multiple Myeloma Hub
Claim This Podcastby Scientific Education Support
3.0(4 reviews)
95 episodes
Updated Weekly
Accepts GuestsHas SponsorsLocation 🇬🇧
36
Podcast Authority
BetaPoorBased on show quality, social media presence, reviews, charts, and more
Quality25
Social0
YouTube86
Engagement31
Podcast Overview
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
Language
🇺🇲
Publishing Since
5/15/2020
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
36
Podcast Authority
BetaPoorBased on show quality, social media presence, reviews, charts, and more
Quality25
Social0
YouTube86
Engagement31
6
Excellent Areas
2
Good Performance
11
Growth Opportunities
excellent
Episode Length
7 minutes
Performing excellently!
good
Show Notes Quality
3.0/5
Recommendations available
Unlock the full report to see detailed tips
needs improvement
Publishing Consistency
Every 28 days
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Multiple Myeloma Hub
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 17, 2026
EHA2026 | DREAMM-8: Early RRMM and sustained MRD-negativity subgroup analyses
<p>During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Meral Beksaç, Istinye University Ankara Liv Hospital, Ankara, TR. We asked about the key findings from two subgroup analyses of the phase III DREAMM-8 trial in RRMM. </p><br><p>The first analysis explored outcomes among patients who received only one prior LoT, while the second examined outcomes in patients who achieved sustained MRD negativity. </p><br><p>This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
July 2, 2026
EHA2026 | What are the latest findings from the phase I CaMMouflage trial evaluating CB-011 in RRMM?
<p>During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Binod Dhakal, Medical College of Wisconsin, Milwaukee, US. We asked, What are the latest findings from the phase I CaMMouflage trial evaluating CB-011 in RRMM?</p><p> </p><p>This educational resource is independently supported by Caribou Biosciences. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
July 2, 2026
Integrating BCMA-directed bispecific antibodies into the treatment paradigm for MM
<p>During the Multiple Myeloma Hub Steering Committee Meeting on May 12, 2026, key opinion leaders met to discuss the integration of B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAbs) into the treatment paradigm for multiple myeloma. The discussion was led by Miles Prince (Peter MacCallum Cancer Centre, Melbourne, AU) and explored key considerations for patient selection, treatment sequencing, and implementation of BsAb therapy in clinical practice. </p><br><p>Prince reviews the currently approved BCMA-directed BsAbs and key factors influencing treatment selection, including disease burden, prior therapy, T-cell fitness, patient preferences, and treatment access. Prince also discusses emerging treatment strategies, including combination regimens and earlier-line use of BsAbs, before exploring practical considerations related to dosing, toxicity management, and community-based treatment delivery. The subsequent discussion focuses on expanding access to BsAb therapy, the role of standardized toxicity management pathways, and challenges associated with transitioning patients from specialist centers to community care. </p><br><p>This educational resource is independently supported by Pfizer. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
95 total episodes available
Similar Podcasts
Discover related shows you might enjoy
Medscape InDiscussion: Multiple Myeloma
Medscape
The Myeloma Minutes
Dr Jam Kothari & Dr Sally Moore
Science Friday
Science Friday and WNYC Studios
Hematologic Oncology Update
Dr. Neil Love
Huberman Lab
Scicomm Media
Core IM | Internal Medicine Podcast
Core IM Team
The Daily
The New York Times
Up First
NPR
The Ezra Klein Show
New York Times Opinion
PBS Washington Week with The Atlantic - Full Show
Washington Week
Hidden Brain
Hidden Brain, Shankar Vedantam
Uncommon Knowledge
Hoover Institution
On Investing
Charles Schwab
Good Hang with Amy Poehler
The Ringer
Blood Podcast
American Society of Hematology
Deep-dive analytics for Multiple Myeloma Hub
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Multiple Myeloma Hub?
- How often does this podcast release new episodes?
This podcast updates weekly.
- Where can I listen to this podcast?
This podcast is available on 9 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.